A Global Dental Leader February 2025 1 Forward-Looking Statements and Non-GAAP Measures Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies, or prospects. We generally use the words "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides, ...

Pricing and Financial Pressures - The company is facing pricing pressures due to cost containment measures in the U.S. and other countries, including a volume-based procurement program in China that resulted in unsuccessful bids[96] - Group purchasing organizations are negotiating pricing arrangements, which may limit the company's ability to sell products to affiliated members if not selected[98] - The company has experienced downward pressure on product pricing and other effects of healthcare reform in international markets, which could adversely affect its financial condition and cash flows[99] - Inflation has increased the overall cost structure, potentially affecting liquidity and financial condition[120] - A 10% price change in raw material commodities would not have a material effect on the company's consolidated financial position, results of operations, or cash flows[260] Debt and Financial Obligations - The company incurred $595.0 million in floating rate indebtedness and prepaid $275.0 million on the term loan, with $221.9 million outstanding as of December 31, 2024[108] - The company has $221.9 million of floating rate debt, and a hypothetical 100 basis points increase in SOFR would raise annual interest expense by $2.2 million[261] - The company does not expect to pay cash dividends for the foreseeable future, as it intends to retain future earnings for business operations and expansion[169] Inventory and Supply Chain Risks - The company is exposed to risks of excess and obsolete inventory, which may adversely impact cash flow and liquidity[116] - The company has entered into supply contracts for raw materials with terms of 12 to 24 months to mitigate commodity price fluctuations[260] International Operations and Currency Risks - Approximately 41% of the company's net sales in 2024 were derived from international markets, indicating a significant reliance on global operations[124] - A significant portion of foreign revenues is generated in Europe and Japan, making the company vulnerable to currency exchange rate fluctuations[117] - The company is exposed to foreign currency exchange rate risks primarily with Euros, Japanese Yen, Canadian Dollars, and Swiss Francs, and manages this risk through derivative financial instruments[259] Regulatory and Compliance Challenges - The company is subject to income taxes in the U.S. and various foreign jurisdictions, with ongoing audits that could materially affect financial statements[121] - The company is subject to stringent FDA regulations for medical devices, which can delay product approvals and impact financial results[131] - Compliance with the EU MDR, effective since May 2021, requires significant expenses and could delay marketing approvals for products in the EU[135] - The company is exposed to healthcare fraud and abuse laws, which could result in substantial penalties and affect business operations[137] - Data privacy and security laws, including the EU GDPR, impose significant compliance costs and potential liabilities for the company[142] - Compliance with new or changing laws related to data protection could result in substantial civil and/or criminal penalties, adversely impacting the business and financial condition[144] Operational and Technological Risks - Implementation of new enterprise resource planning (ERP) systems has caused disruptions, impacting operating results in 2022, with potential for similar issues in 2025 and beyond[100] - The company is increasingly dependent on sophisticated information technology, and failure to maintain or protect information systems could adversely affect operations[146] - Cyber-attack attempts are becoming more frequent and sophisticated, posing risks to business operations and reputation[149] Legal and Environmental Risks - The company bears the risk of warranty claims on products, which could exceed warranty reserves and harm financial condition[150] - Intellectual property rights are crucial for the company, and failure to protect these rights could result in significant monetary damages and impact product sales[151] - The company is involved in various legal proceedings that could result in adverse outcomes, potentially harming financial results[154] - The business involves the use of hazardous materials, and compliance with environmental laws may incur significant costs and restrict operations[156] - Climate change poses risks to operations from natural disasters, which could increase operational costs and impact supply chains[157] Market and Stock Performance - The market price of the company's common stock may be volatile, influenced by various factors including operating results and market conditions[167] - Analysts' research and reports significantly influence the trading market for the company's common stock, and unfavorable reports could lead to a decline in stock price[164] - The company has significant credit risk concentrations in public and private hospitals and dental practices, particularly in Europe, which are subject to government budget constraints[263] Foreign Regulatory and Trade Risks - The company faces risks from changes in foreign regulatory requirements, currency fluctuations, and trade barriers that could increase operating costs[125] - Zimmer Biomet may require indemnification for additional taxes resulting from acquisitions, which could materially impact the company's financial results[162]

Exhibit 99.1 ZimVie Reports Fourth Quarter and Full Year 2024 Financial Results PALM BEACH GARDENS, Florida, February 26, 2025 (GLOBE NEWSWIRE) – ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today reported financial results for the quarter and year ended December 31, 2024. Management will host a corresponding conference call today, February 26, 2025, at 4:30 p.m. Eastern Time. "2024 was a transformational year for ZimVie. We became a pure play dental companyand reshaped ou ...

Core Insights - ZimVie Inc. reported a transformational year in 2024, becoming a pure play dental company and reducing net debt by over $290 million [2] - The company achieved an increase in Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023, despite a softer end market [2] - ZimVie is optimistic about the long-term growth drivers in the dental implant market, supported by successful training and education programs [2] Financial Performance - Q4 2024 - Third-party net sales for Q4 2024 were $111.5 million, a decrease of 1.4% on a reported basis and 0.9% in constant currency compared to Q4 2023 [3] - The net loss for Q4 2024 was $(9.7) million, an improvement of $12.5 million from a net loss of $(22.2) million in Q4 2023 [4] - Adjusted net income for Q4 2024 was $7.6 million, an increase of $5.0 million from Q4 2023 [4] Financial Performance - Full Year 2024 - Total third-party net sales for the full year 2024 were $449.7 million, a decrease of 1.6% on a reported basis and 1.2% in constant currency compared to 2023 [6] - The net loss for the full year 2024 was $(33.8) million, an improvement of $22.2 million from a net loss of $(56.0) million in 2023 [7] - Adjusted EBITDA for the full year 2024 was $60.0 million, or 13.3% of third-party net sales, an increase of $9.2 million from 2023 [8] Financial Guidance for 2025 - Projected net sales for FY2025 are expected to be between $445 million and $460 million, reflecting a growth of (1%) to 2% [11] - Adjusted EBITDA for FY2025 is projected to be between $65 million and $70 million, indicating an increase of 8% to 17% [11] - Adjusted EPS for FY2025 is expected to be between $0.80 and $0.95, representing a growth of 29% to 53% [11] Company Overview - ZimVie Inc. is a global leader in the dental market, focusing on developing and delivering products for dental tooth replacement and restoration procedures [13] - The company aims to improve smiles and confidence through its comprehensive portfolio, including dental implants and digital workflow solutions [13]

Core Viewpoint - ZimVie Inc. will report its financial results for Q4 and full-year 2024 on February 26, 2025, after market close, followed by a conference call at 4:30 p.m. Eastern Time [1]. Company Overview - ZimVie is a global leader in the dental market, focusing on developing, manufacturing, and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [2]. - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide, aiming to enhance smiles, function, and confidence through its dental solutions [2]. - ZimVie offers a range of products including dental implants, biomaterials, and digital workflow solutions, and is committed to advancing clinical science and technology in the dental field [2].

Core Insights - ZimVie Inc. has published a scientific study indicating that its premium dental implants may reduce the risk of peri-implant infections compared to other implants available in the market [1][2][3] Group 1: Study Findings - The study, published in the Journal of Biomedical Materials Research, evaluated ZimVie's dual acid-etched coronal surface technology against other leading implant brands [2] - The research highlights a critical threshold roughness for implant surfaces, where rougher surfaces increase bacterial adhesion, while ZimVie's implants maintain adhesion levels comparable to smooth machined surfaces [3] - ZimVie's Contemporary Hybrid Surface technologies are designed to mitigate the rising prevalence of peri-implant mucositis and peri-implantitis [3] Group 2: Product Information - TSX Implants, launched in 2022, are engineered for immediate extraction and standard loading protocols, focusing on primary stability and crestal bone maintenance [4] - T3 PRO Implants, also launched in 2022, feature a hybrid surface design that promotes high primary stability and immediate function, with clinical studies supporting their safety and performance [5] Group 3: Company Overview - ZimVie is a global leader in the dental market, dedicated to developing and delivering a comprehensive range of products for dental tooth replacement and restoration [7] - The company operates from its headquarters in Palm Beach Gardens, Florida, and aims to enhance patient outcomes through advanced clinical science and technology [7]

Financial Data and Key Metrics Changes - Total revenue for Q3 2024 was $103 million, reflecting a decrease of 2% in reported rates and a decline of 2.2% in constant currency compared to the prior year [13] - Adjusted EBITDA for continuing operations was $13.1 million, resulting in a 12.7% adjusted EBITDA margin, an improvement from 11.6% in the prior year [16] - Adjusted earnings per share attributable to continuing operations was $0.12 per share on a fully diluted share count of 27.6 million shares [17] Business Line Data and Key Metrics Changes - U.S. third-party net sales were $65.4 million, an increase of 0.5%, with a 1.6% growth when excluding oral scanner sales [13] - The biomaterials portfolio grew at a healthy rate, serving as a leading indicator for future implant procedures [8] - The digital portfolio, excluding iTero scanner sales, grew over 10% in Q3, driven by the adoption of RealGUIDE 5.4 software and the Medit partnership [9] Market Data and Key Metrics Changes - Outside the U.S., third-party net sales decreased by 6% on a reported basis, primarily due to order timing in Japan and Italy, and a slower market in Spain [14] - The company noted resilience in the U.S. dental market, with modest overall year-over-year growth [6] Company Strategy and Development Direction - The company is focused on improving manufacturing efficiency and decreasing the cost of products sold [4] - Investments are being made in sales teams, training programs, and R&D to fill product portfolio gaps and capitalize on market opportunities [5] - The company aims to achieve a 15% plus adjusted EBITDA margin one year post the sale of its Spine business [19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in North America returning in Q4 2024 [23] - The company is confident in its positioning for future growth, particularly in the U.S. market, which is the most profitable [34] - Management highlighted that the digital business is a significant growth enabler, with a focus on underpenetrated markets [36] Other Important Information - The company paid down $15 million in debt, resulting in a gross debt of $220 million and a net debt of $153 million [5] - The company is narrowing its full-year revenue guidance range to $450 million to $455 million [19] Q&A Session Summary Question: How is the company thinking about the recovery in the U.S. market? - Management feels optimistic about growth in North America returning in Q4, with expectations for Japan to resume growth as well [23][24] Question: Have patients started returning for implants, and can the company size that backlog? - Management has not quantified the patient backlog but believes biomaterials are a leading indicator of future implant procedures [26] Question: Can the company sustain the current gross margin levels? - Management is pleased with the gross margin performance and expects it to remain stable moving forward [28] Question: What is the confidence level in volumes for Q4 and entering next year? - Management is comfortable with the year-end guidance and sees positive trends in the North American market [34] Question: How is the digital side of the business performing? - The digital business has seen significant growth, with RealGUIDE software growing over 30% year-over-year [36]

Financial Performance - Total net sales for the three months ended September 30, 2024, were $103.2 million, a decrease of 2.0% compared to $105.3 million in the same period of 2023[84]. - For the nine months ended September 30, 2024, total net sales were $338.2 million, down 1.8% from $344.4 million in 2023[85]. - The company experienced a price decline of 1.1% in net sales for the nine months ended September 30, 2024, primarily due to pricing pressures in North America and China[85][87]. - Foreign exchange fluctuations had a small positive effect on year-over-year sales for the three months ended September 30, 2024, mainly due to the strengthening of the Euro[88]. Expenses - Research and development expenses increased to 6.7% of net sales in the three months ended September 30, 2024, compared to 5.4% in the same period of 2023[92]. - Selling, general and administrative expenses rose to 55.5% of net sales in the three months ended September 30, 2024, up from 53.7% in the prior year[89]. - Cost of products sold as a percentage of net sales decreased to 34.7% in the three months ended September 30, 2024, from 35.0% in the same period of 2023[89]. - Restructuring and other cost reduction initiatives recognized expenses of $0.7 million in the three months ended September 30, 2024, compared to $1.4 million in the same period of 2023[95]. Cash Flow and Liquidity - Cash and cash equivalents were $68.1 million as of September 30, 2024, down from $87.8 million at the end of 2023[103]. - Cash flows from operating activities were $(7.3) million for the nine months ended September 30, 2024, compared to $15.7 million in the same period of 2023[104]. - Cash flows from investing activities were $285.2 million for the nine months ended September 30, 2024, primarily from the sale of the spine segment[105]. - Cash flows used in financing activities were $295.4 million for the nine months ended September 30, 2024, including a $275.0 million prepayment on the Term Loan[106]. - The company believes available cash and cash equivalents will be sufficient to meet liquidity needs for at least the next 12 months[108]. Debt and Interest - As of September 30, 2024, the company had $221.9 million of floating rate debt subject to SOFR, with a potential $2.2 million decrease in annual pre-tax results from a 100 basis points increase in SOFR[113]. - Interest income increased due to the promissory note from the sale of the spine segment[98]. - Interest expense decreased due to a reduction in outstanding debt and interest rates[99]. Legal Matters - The company is subject to various claims and legal proceedings, but does not expect a material adverse impact on results of operations, cash flows, or financial position[119]. - The outcome of legal matters is unpredictable and could have a material adverse effect on financial position, results of operations, or cash flows[119]. Other Significant Events - The company recorded a gain of $11.3 million from the sale of its spine segment, which was completed on April 1, 2024, for a total purchase price of $377.2 million[75]. - The company initiated restructuring activities in January 2024 to better support its dental segment following the sale of the spine segment[80]. - Other income related to TSA income was $3.2 million and $6.6 million for the three and nine months ended September 30, 2024 and 2023, respectively[97]. - The effective tax rate (ETR) on loss before income taxes was 18.4% for Q3 2024 compared to (3.3%) for Q3 2023[100]. - There were no changes in internal control over financial reporting during the three months ended September 30, 2024[117].

Financial Performance - Third party net sales for Q3 2024 were $103.2 million, a decrease of 2.0% on a reported basis and 2.2% in constant currency compared to Q3 2023[3]. - Net loss for Q3 2024 was $(3.0) million, an improvement of $7.2 million from a net loss of $(10.2) million in Q3 2023, with a net loss margin of 3.0%[4]. - Adjusted EBITDA for Q3 2024 was $13.1 million, representing a margin of 12.7%, an increase of $0.9 million or 110 basis points from Q3 2023[5]. - Adjusted net income for Q3 2024 was $3.3 million, an increase of $2.1 million compared to Q3 2023[4]. - Adjusted diluted EPS for Q3 2024 was $0.12, while basic and diluted EPS were $(0.11)[5]. - The net loss margin improved by 670 basis points from 9.7% in Q3 2023 to 3.0% in Q3 2024[4]. - The company reported a basic loss per share from continuing operations of $(0.11) for the three months ended September 30, 2024, compared to $(0.38) for the same period in 2023[17]. - Adjusted Net Income for the three months ended September 30, 2024, was $3,283 thousand, resulting in a Diluted EPS of $0.12, compared to a Diluted EPS of $(0.38) in 2023[22]. Sales and Revenue - Total net sales for the three months ended September 30, 2024, were $103,222, a decrease of 2.0% compared to $105,311 for the same period in 2023[17]. - U.S. Dental Net Sales for the nine months ended September 30, 2024, were $202,414 thousand, down 0.9% from $204,173 thousand in 2023[20]. - International Dental Net Sales for the three months ended September 30, 2024, decreased by 6.0% to $37,872 thousand from $40,308 thousand in 2023[20]. - Total Third Party Sales for the nine months ended September 30, 2024, were $338,228 thousand, down 1.7% from $344,131 thousand in 2023[24]. - The company reported a Constant Currency % Change in Total Dental Net Sales of (2.2%) for the three months ended September 30, 2024[20]. Guidance and Projections - The company updated its full-year 2024 guidance, projecting net sales of $450 million to $455 million and adjusted EBITDA of $60 million to $62 million[5]. Expenses and Costs - Cost of products sold for Q3 2024 was $(35,820) thousand, a decrease from $(36,907) thousand in Q3 2023, representing a 2.9% reduction[25]. - Adjusted cost of products sold, excluding intangible asset amortization, was $(35,533) thousand in Q3 2024, compared to $(36,614) thousand in Q3 2023, reflecting a 2.9% decrease[25]. - Research and development expenses for Q3 2024 totaled $(6,926) thousand, up from $(5,677) thousand in Q3 2023, indicating an increase of 22.1%[25]. - Selling, general and administrative expenses for Q3 2024 were $(57,313) thousand, slightly higher than $(56,505) thousand in Q3 2023, a 1.4% increase[25]. - The percentage of adjusted cost of products sold to net sales for Q3 2024 was 34.4%, slightly lower than 34.8% in Q3 2023[25]. Cash Flow and Assets - Cash and cash equivalents decreased to $66,808 as of September 30, 2024, from $71,511 as of December 31, 2023[18]. - Total assets decreased to $782,948 as of September 30, 2024, from $1,205,345 as of December 31, 2023[18]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $(7,276), compared to $15,694 for the same period in 2023[19]. Company Strategy and Investments - The company is focusing on operational improvements and has made investments in sales force, R&D initiatives, and training programs for future expansion[2]. - The company is committed to advancing clinical science and technology in the dental market, focusing on product development and market expansion[7]. Other Financial Metrics - The company incurred $(20,285) thousand in research and development expenses for the nine months ended September 30, 2024, compared to $(19,365) thousand in the same period of 2023, an increase of 4.7%[25]. - The company reported a net impact of $(476) thousand from share-based compensation modification in Q3 2024, compared to no such expense in Q3 2023[25].

Core Viewpoint - ZimVie Inc. will report its financial results for Q3 2024 on October 30, 2024, after market close, with a conference call scheduled for 4:30 p.m. Eastern Time [1]. Company Overview - ZimVie is a global leader in the dental market, focusing on developing, manufacturing, and delivering a comprehensive portfolio of products for dental tooth replacement and restoration [2]. - The company is headquartered in Palm Beach Gardens, Florida, and operates additional facilities worldwide, aiming to enhance smiles, function, and confidence through its dental solutions [2]. - ZimVie offers a range of products, including dental implants, biomaterials, and digital workflow solutions, and is committed to advancing clinical science and technology in the dental field [2].